TCT 2021: RADIANCE-HTN: 6Mo Outcomes of RDN Vs a Sham Procedure for Resistant Hypertension

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

In this short summary interview, Dr. Ajay Kirtane (Columbia University Medical Center, US) shares the six-month outcomes of a randomized trial of renal denervation (RDN) versus a sham procedure for resistant hypertension. The RADIANCE-TRIO Trial, presented first at TCT 2021, showed that he additional effects of pharmacologic intervention with maintenance of a BP-lowering effect of endovascular ultrasound RDN at 6 months, mirroring the results of the RADIANCE SOLO trial.

Discussion Points
RADIANCE-HTN in the Context of Other Studies
Design and Eligibility Criteria
Key Findings
Which Patient Would Benefit from RDN
Take-home Messages for Interventionists
Next Steps

Recorded remotely from New York, 2021.

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.